Background {#Sec1}
==========

High-risk human papilloma viruses (HPV) are acknowledged as causing cancers of the cervix, anus, vulva, vagina, penis and oropharynx. The incidence of HPV-associated anogenital and oropharyngeal cancers is rising in the developed world and is a major cause of morbidity and mortality across low and middle-income countries. Approximately 5% of all cancers worldwide are caused by HPV^[@CR1]^ with the proportion of cancers attributable to HPV at each site ranging from 50% (vulval) to \~90% (anal).^[@CR2]^ Cancers arising at these sites have marked biological similarities^[@CR3]^ and treatment protocols. Many HPV-associated cancers and precancerous lesions (termed intraepithelial neoplasia) present with early disease and cure rates following surgical excision (i.e. for early-stage cervical cancers or anal intraepithelial neoplasia) are excellent.^[@CR4],[@CR5]^ For patients with locally advanced disease (for example head and neck or anal squamous cell carcinomas) treatment typically involves radical chemo-radiotherapy, with relatively high rates of long-term survival.^[@CR6],[@CR7]^

Although patients diagnosed with primary HPV-associated cancers then are often cured, they remain at risk of second HPV-associated malignancies. A number of factors likely contribute to this increased risk including prior exposure to high-risk subtypes of HPV where sexual behaviour promulgates this risk.^[@CR8]^ Intra-patient transmission of HPV across the various anatomical sub sites of the anogenital regions is recognised. Additionally, there is evidence to support underlying biological susceptibility to HPV-associated cancers where candidate gene approaches or genome-wide association studies suggest that polymorphisms within immune pathways might play a role. Variants of the TGF beta receptor 1 have been associated with HPV-associated head and neck cancer ^[@CR9]^ and MHC variants linked with cervical cancer.^[@CR10]^ A number of registry and other studies report incidence rates of second primary HPV-associated cancer, typically focussing on a single primary tumour and a subset of the potential second cancers. However, a more accurate estimate of this risk is required following treatment of the initial cancer to understand the need for and inform the design of follow-up and surveillance protocols. It would also facilitate the investigation of additional treatments in the future such as novel screening or therapeutic vaccination strategies to reduce the risk of second cancers.

We therefore conducted a systematic literature review and meta-analysis to estimate the overall rates of second HPV-associated cancers following treatment of an initial such tumour.

Methods {#Sec2}
=======

A protocol, including the full methods for this review, is available from <http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016046974>.

Study eligibility {#Sec3}
-----------------

### Systematic review {#Sec4}

To be comprehensive, studies were considered eligible for inclusion in the systematic review if they reported second HPV-associated cancers after an initial index cancer (or preinvasive, in situ neoplasia) at a site associated with HPV infection, i.e. invasive cervical, vaginal, vulval, anal, or penile cancers or their associated preinvasive lesions (CIN/VAIN/VIN/AIN/PIN) or cancers of the oropharynx (tonsil and tongue base). These included previous systematic reviews, cohort studies including from cancer registries, and phase III trials of radical treatment that report second cancers. All eligible studies were included in the results of the systematic review.

### Meta-analysis {#Sec5}

To limit ascertainment bias, only studies that measured and reported the same statistics using the same measures were included in the formal meta-analysis. Studies reporting the risk of second cancers in a population affected by the primary index cancer compared with the risk of those cancers in a contemporary control population not affected by the primary cancer (e.g. derived from SEER data) were eligible for inclusion in the meta-analysis. Specifically, this must have been presented as a standardised incidence ratio (SIR), calculated by dividing the observed incidence of second primary malignancies (SPM) by the incidence for the general population, measured from the rest of the registry unaffected by the primary cancer in question.^[@CR11]^

Study identification {#Sec6}
--------------------

To identify eligible studies that reported subsequent incidences of cancers including, but not limited to, those known to be associated with HPV after an initial diagnosis, we developed a comprehensive search strategy for MEDLINE. The search strategy included MeSH and free-text terms for each of the HPV-associated cancer sites or precancerous in situ disease states, namely cervix, vagina, vulva, oropharynx, penis and anus, as well as for each of the relevant study types and for second primary cancer. The strategy used is given in Appendix 1 (supplementary material). Web of Science, ASCO, ESMO/ECCO databases and conference proceedings of the International Papillomavirus Society (IPVS) were also searched for relevant articles or abstracts. Reference lists of included articles were manually screened to retrieve any additional eligible studies. Searches were updated until 7 July 2016.

Data extraction {#Sec7}
---------------

Data were extracted from the reports of all studies identified as being eligible for inclusion in the systematic review using a predefined form, including where available: origin of patient population (registry, single centre cohort, randomised trial cohort); time points of initial diagnosis; number at risk; subsequent incidence of HPV-associated cancers and precancerous in situ disease of the anogenital region (cervical, vulval, vaginal, penile, anal) and the oropharynx (specifically, base of tongue and tonsil). In addition, for studies to be included in the formal meta-analysis, SIR and associated statistics for each second primary HPV-associated cancer were also extracted.

Risk of bias/quality assessment of studies {#Sec8}
------------------------------------------

Since all eligible studies were of cohort design, the Newcastle--Ottawa quality assessment scale^[@CR12]^ was used to evaluate methodological quality. A meta-analysis of observational studies in epidemiology (MOOSE) checklist ^[@CR13]^ was completed and is included in the Supplementary Materials.

Statistical analysis {#Sec9}
--------------------

Absolute numbers of second cancers and associated standardised incidence rates (SIR)^[@CR11]^ were tabulated from each study, organised according to the site of index primaries. Where SIR for relevant individual sites of second primary cancer (vulval and vaginal cancers or tonsil and tongue base) were reported separately, data were pooled using a random effect meta-analysis to obtain a single SIR for the combined site (i.e. vulvo-vaginal and oropharyngeal).

For each second cancer type (cervix, anal, oropharynx, penile and vulvo-vaginal) the SIRs and associated statistics from the individual studies were combined in a formal meta-analysis according to the index cancer site, to obtain an estimate of the risk of independent second primary cancer following individual index primaries. Chi-square tests for interaction were used to investigate whether there were any substantial differences in the risk of second primary cancers between groups of studies based on primary cancer type. SIRs and associated statistics for second primary cancer at the same location as the index HPV-associated cancer were considered separately.

Statistical heterogeneity and inconsistency^[@CR14]^ were also assessed within the subgroups of studies based on the index HPV-associated cancer for each second primary cancer type. To account for expected heterogeneity between studies, a random effects meta-analysis model was used.^[@CR15]^ Analyses were conducted using the IPDmetan command^[@CR16]^ in Stata version 14.

Results {#Sec10}
=======

Eligible studies {#Sec11}
----------------

Searches returned 5599 titles, which were screened for eligibility (Fig. [1](#Fig1){ref-type="fig"}). Sixty studies fulfilled the criteria for the systematic review; however, 18 studies^[@CR17]--[@CR32]^ reported institutional cohorts with absolute numbers of second primaries (Table S[1](#MOESM1){ref-type="media"}) and a further 10 studies^[@CR33]--[@CR42]^ reported second primaries and SIRs without providing either confidence intervals or standard errors (Table [S2](#MOESM1){ref-type="media"}), so they could not be included in the formal meta-analyses. The remaining 32 studies^[@CR43]--[@CR74]^ from large institutional, regional or national cancer registries (representing 16 countries), all reported SIRs and associated statistics and are therefore included in the meta-analysis (two pairs of studies reported overlapping data from the same sources and were combined). These 32 studies comprised 3,759,726 patients and yielded 98 comparisons of individual sites of HPV-associated cancer after an index case. Characteristics of the 32 studies are shown in Table [1](#Tab1){ref-type="table"}. All 32 studies were assessed as having reasonable quality (score range: 5−8) according to the Newcastle Ottawa framework. A MOOSE checklist^[@CR13]^ is included in the supplementary materials.Fig. 1PRISMA flow diagram of identification and selection of eligible studies. \*Included in discussion with respect to estimation of absolute risk of subsequent HPV-associated cancer, Table S[1](#MOESM1){ref-type="media"}. ^\#^Included in Table S[2](#MOESM1){ref-type="media"}Table 1Studies reporting SIR for second primary HPV cancers after an initial HPV-associated tumourAuthor^ref.^Study typeCountry and data sourceStudy population, definition and inclusion criteriaPrimary cancer diagnosis timeframe and follow-up duration*N*Second primary cancer type(s); number of casesSIR (95% CI)NotesFirst primary cancer: Cervical/CIN Bjorge et al.^[@CR43]^Retrospective cohort studyNorway; Cancer Registry of NorwayWomen with diagnosis of cervical carcinoma in situ; second cancer diagnosis ≥ 1 year following CIS diagnosis1970−1992; 9.1 years (mean)37,001Cervix; 11Oropharynx; 9Vulvo-vaginal; 321.26 (0.6−2.3)2.88 (2.43−3.42)4.04 (2.76−5.70)Incidence of second primary tongue and tonsil reported separately and pooled for this analysis Chaturvedi (same data set)^[@CR44],\ [@CR45]^Retrospective cohort studyDenmark, Finland, Norway, Sweden,USA; data from 13 population-based cancer registriesOne-year survivors of cervical cancer1943--2001;12.2 years (mean)104,760Vulvo-vaginal; 497Anal; 817Oropharynx; 844.81 (4.40−5.25)1.84 (1.72−1.98)1.49 (0.97−2.29)Incidence of second primary tongue and pharynx reported separately and pooled for this analysis Chen^[@CR46]^Retrospective cohort studyTaiwan;Taiwan Cancer RegistryWomen with initial diagnosis of cervical cancer and complete data available1979−2008;8.18 years (mean)52972Vulvo-vaginal; 137Oropharynx; 3710.48 (8.80−12.39)1.18 (0.83−1.62) Edgren and Sparen^[@CR47]^Retrospective cohort studySweden;Swedish Cancer RegisterWomen with diagnosis of CIN Grade 3 diagnosis; second cancer diagnosis ≥ 1 year following CIN diagnosis1968−2004;27 years (median)2,302,024Vulvo-vaginal; 173Anal; 1313.74 (1.55−9.04)2.81 (1.29−5.44)Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Evans et al.^[@CR48]^Retrospective cohort studyUK; Thames Cancer RegistryWomen with a diagnosis of CIN 3Women with a diagnosis of cervical cancer1960−1999;8.0 years (mean)1960−1999;6.7 years (mean)59,57921,605Cervix; 194Vulvo-vaginal; 61Anal; 23Oropharynx; 20Cervix; 3Vulvo-vagina; 26Anal; 18Oropharynx; 162.8 (2.4-3.2)9.08 (2.22−37.09)5.9 (3.7−8.8)1.2 (0.8−1.9)0.1 (0−0.3)3.91 (0.96−16.01)6.3 (3.7−10.0)1.4 (0.8−2.2)Study reports second cancer incidences according to whether the primary event was CIN 3 or invasive cancer.Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Fisher et al.^[@CR49]^Retrospective cohort studyUSA; Michigan Cancer Surveillance Records and US census dataWomen living in Michigan, diagnosed and registered with cancers of the lower anogenital tract1985--1992;8 years (maximum)1565Cervical; 5Vulvo-vaginal; 63.6 (1.2−8.3)44.3 (16.2−96.5) Gaudet et al.^[@CR50]^Retrospective cohort studyCanada; British Columbia Cancer Agency cervical cancer screening programme database and British Columbia Cancer RegistryWomen with pathological diagnoses of CIN 2 or 31985−2005;10.1 years (median)54,320Vulvo-vaginal; 143Anal; 204.20 (1.87−9.43)1.75 (0.43−4.65)Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Hemminki et al.^[@CR51]^Retrospective cohort studySweden;Swedish Family Cancer Database and Swedish Cancer RegistryWomen with diagnoses of primary invasive cervical cancer1958−1996;Average follow-up unknown17,234Cervix; 46Genital; 67Anal; 16Oropharynx; 330.84 (0.62−1.10)5.91 (4.58−7.41) 4.22 (2.41−6.55)2.20 (1.51−3.01) Hemminki et al.^[@CR52]^Retrospective cohort studySweden;Swedish Family Cancer Database and Swedish Cancer RegistryWomen with diagnoses of CIS1958−1996;Average follow-up unknown117,830Cervix; 758Genital; 155Anal; 68Oropharynx; 792.30 (2.14−2.47)3.68 (3.12−4.28)3.75 (2.91−4.69)1.69 (1.33--2.08) Jakobsson et al.^[@CR53]^Retrospective cohort studyFinland;Finnish National Hospital Discharge Register and Finnish Cancer RegistryWomen receiving surgical treatment for CIN1986−2004;8.4 years (mean)26,876Cervix; 23Vulvo-vaginal; 17:Anal; 31.69 (1.07--2.53)6.84 (4.08−11.48)3.56 (0.73−10.4)Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Kalliala et al.^[@CR54]^Retrospective cohort studyFinland; Finnish Population Registry and Finnish Cancer RegistryWomen receiving surgical treatment for CIN at Helsinki Central University Hospital1974−2001;11.9 years (mean)7564Cervix; 22Vulvo-vaginal; 11Anal; 32.8 (1.7−4.2)6.86 (2.40−19.65)5.7 (1.2−17.0)Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Levi et al.^[@CR55]^Retrospective cohort studySwitzerland; Swiss Cancer Registry of VaudWomen with diagnoses of CIS1974−199310.1 years (average)2190Cervix; 103.4 (1.6−6.3) Lim et al.^[@CR56]^Retrospective cohort studySouth Korea;Korea Central Cancer RegistryWomen diagnosed with cervical cancer1993−2010;7.34 years (mean)72,805Vulvo-vaginal; 24Anal; 11Oropharynx; 94.98 (1.41−17.61)2.42 (1.21−4.32)1.33 (0.63--2.78)Incidence of second primary vulva and vaginal cancers and tongue and tonsillar cancers reported separately and pooled for this analysis Mitchell et al.^[@CR57]^Retrospective cohort studyAustralia; Victorian Cytology Gynaecological Service recordsWomen with a histologically confirmed diagnosis of CIN1974−1976;1281Cervix; 619.8 (2.4−163.5) Neumann et al.^[@CR58]^Retrospective cohort studyFrance; K2 databaseMen and women with potentially HPV-related primary cancer diagnoses1989−2004;3.1 years (median)6049 womenVulvo-vaginal; 8Anal; 511.74 (5.23−25.99)5.42 (1.75−12.64)Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Rabkin et al.^[@CR59]^Retrospective cohort studyUSA; Connecticut Tumor Registry and National Cancer Institute SEER databaseWomen with first primary cervical cancer1935−1988 /1973−1988;8.5 years9325Vulvo-vaginal; 54Anal; 12Oropharynx; 475.6 (4.2−7.4)4.6 (2.4−8.1)2.2 (1.6--2.9)Connecticut registry 1935−1988; Other US registries 1973−1988 Rose Ragin and Taioli^[@CR60]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseWomen with first primary cervical cancer1973−2002;Average follow-up not reported2618Vulvo-vaginal: number of cases not reported:Anal: number of cases not reported:Oropharynx; 129.37 (2.96−29.79)2.9 (1.7−4.5)2.7 (1.4--4.7)Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Saleem et al.^[@CR61]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseWomen with a confirmed diagnosis of CIN; \> 15 years old1973--2007;15.7 years (mean)124075Anal; 13716.4 (13.7-19.2) Saleem et al.^[@CR61]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseWomen with a confirmed diagnosis primary cervical cancer; \>15 years old1973−2007;11.4 years (mean)43,669Anal; 286.2 (4.1−8.7) Sand et al.^[@CR62]^Retrospective cohort studyDenmark; Danish civil Registration system and Danish Cancer RegistryWomen born between 1918 and 1990, resident in Denmark between 1978 and 2012 with histological confirmation of CIN2 or CIN31978−2012;11.5 years (mean)1978−2012;14.7 years (mean)52,135 (CIN2)104,155 (CIN3)Vulvo-vaginal; 34Anal; 32Vulvo-vaginal; 168Anal; 1254.41 (1.39−13.94)2.9 (2.0−4.1)8.24 (1.99−34.22)4.2 (3.5−4.0)Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Strander et al.^[@CR63]^Retrospective cohort studySweden; Swedish Cancer RegistryWomen diagnosed and treated for CIN31958−2002Average follow-up not reported132,493Cervical; 881Vaginal; 1112.34 (2.18−2.50)6.82 (5.61−8.21) Svahn et al.^[@CR64]^Retrospective cohort studyDenmark; Danish Cancer Registry and danis Pathology DatabankWomen born between 1918 and 1990, living in Denmark 1995−2012 and diagnosed with CIN31995−2012Average follow-up not reported101,974Oropharyngeal; 472.51 (1.86−3.39)First primary cancer: Vulvo-vaginal/VIN Hemminki et al.^[@CR51]^Retrospective cohort studySweden;Swedish Family Cancer Database and Swedish Cancer RegistryWomen with diagnoses of primary invasive genital cancer1958−1996;Average follow-up unknown2528Cervical; 7Genital ; 15Anal; 6Oropharynx; 91.88 (0.75−3.54)8.81 (4.92−13.84)13.97 (5.03−27.39) 4.65 (2.11−8.19) Neumann et al.^[@CR58]^Retrospective cohort studyFrance; K2 databaseMen and women with potentially HPV-related primary cancer diagnoses1989−2004;3.1 years (median)6049 women*Vaginal primary*:Cervical; 2*Vulvar primary*:Cervical; 3Vaginal; 1Anal; 113.70 (1.54--49.45)12.10 (2.43−35.36)25.84 (0.34−143.95)11.77 (0.15−65.51)Reported separately for primary vulvar and vaginal cancers Saleem et al.^[@CR61]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseWomen with a confirmed diagnosis of VIN; \>15 years old1973−2007;8.9 years (mean)6792Anal; 5522.2 (16.7−28.4) Saleem et al.^[@CR61]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseWomen with a confirmed diagnosis of invasive vulvar cancer; \>15 years old1973--2007;7.1 years (mean)9950Anal; 2817.4 (11.5−24.4) Saleem et al.^[@CR61]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseWomen with a confirmed diagnosis of Vaginal in situ; \>15 years old1973−2007; 11 years (mean)1463Anal; 57.6 (2.4−15.6) Saleem et al.^[@CR61]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseWomen with a confirmed diagnosis of invasive vaginal cancer; \>15 years old1973−2007; 4.5 years (mean)3257Anal; 251.8 (0.2−5.3)First primary cancer: Anal/AIN Frisch et al.^[@CR65]^Matched case-control study usingDenmark; Danish Cancer Registry (cases) and Central population register (controls)Patients with diagnoses of primary invasive epidermoid anal cancer1943−1989;Average follow-up (men): 5.1 yearsAverage follow-up (women); 5.6 years955Cervical; 2Vulvo-vaginal; 5Penile; 71.6 (0.1−4.5)12.3 (4.0−28.7)1.8 (0.7−3.7) Hemminki et al.^[@CR51]^Retrospective cohort studySweden;Swedish Family Cancer Database and Swedish Cancer RegistryMen and women with diagnoses of primary invasive anal cancer;1958−1996;Average follow-up unknown334 men744 womenGenital; 2Oropharyngeal; 2Cervical; 1Genital; 2Anal; 1Oropharyngeal; 360.24 (5.68--172.66)6.78 (0.64--19.42)1.12 (0.00--4.39)4.73 (0.45−13.55)7.07 (0.00−27.71)6.01 (1.13−14.75) Neumann et al.^[@CR58]^Retrospective cohort studyFrance; K2 databaseMen and women with potentially HPV-related primary cancer diagnoses1989−2004;3.1 years (median)6049 womenCervical; 2Oropharyngeal; 22.95 (0.3--10.66)19.28 (2.17−69.60) Rabkin et al.^[@CR59]^Retrospective cohort studyUSA; Connecticut Tumor Registry and National Cancer Institute SEER databaseMen and women with first primary anal cancer1935−1988/1973−1988; 5.12 years530Cervical; 2Vulvo-vaginal; 2Oropharynx; 411.3 (0.2−4.5)2.5 (0.3−9.4)1.0 (0.3--2.6)Connecticut registry 1935−1988; Other US registries 1973−1988 Shah and Budhathoki^[@CR66]^Retrospective cohort studyUSA; National Cancer Institute SEER databasePatients with a primary diagnosis of anal carcinoma1992−2013;87 months (median)7661 (Men: 3196; Women: 4465)Vulvo-vaginal; 24Anal; 56Penile; 110.154 (6.61−15.60)30.87 (23.32−40.09)2.93 (0.07−16.33)Incidence of second primary vulva and vaginal cancers reported separately and pooled for this analysis Sikora et al.^[@CR67]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseMen with primary anal cancer diagnoses; aged 20 years or greater1973−20045.3 years median2080Oropharyngeal; 105.99 (2.98--12.05)Incidence of second primary tongue and tonsil reported separately and pooled for this analysisFirst primary cancer: Penile/PINHemminki et al.^[@CR51]^Retrospective cohort studySweden;Swedish Family Cancer Database and Swedish Cancer RegistryMen with diagnoses of primary invasive genital cancer1958−1996;Average follow-up unknown1127Genital; 3Oropharyngeal; 212.71 (2.40--31.15)2.57 (0.81--5.32) Sikora et al.^[@CR67]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseMen with primary penile cancer diagnoses;1973−2004;6.7 years median2217Oropharyngeal; 124.74 (2.54--8.85)Incidence of second primary tongue and tonsil reported separately and pooled for this analysisFirst primary cancer: Head and neck (oropharynx) Bhattacharyya^[@CR68]^Retrospective cohort studyUSA;National Cancer Institute SEER databaseCases from the SEER programme with primary head and neck cancer1988−1999;Follow-up: 42.2 months (mean) Minimum follow-up at least 3 m4122Oropharyngeal: Number of cases not reported5.951 (3.611−9.808)Number of cases of second primary cancer not reported Bosetti^[@CR69]^ Chuang^[@CR70]^ (same data set)Retrospective cohort studyAustralia,Canada,Denmark,Finland,Norway,Scotland,Singapore,Slovenia,Sweden,Spain; data from 13 population-based cancer registriesCases with primary head and neck cancer diagnoses1943−2000;4.9 years (mean)99,257Oropharyngeal; 76013.67 (10.06−18.58)Incidence of second primary tongue and pharynx reported separately and pooled for this analysis †Hemminki et al.^[@CR51]^Retrospective cohort studySweden;Swedish Family Cancer Database and Swedish Cancer RegistryMen and women with diagnoses of primary invasive oral cancers1958−1996;Average follow-up unknown10,780 (men)3366 (women)Anal; 2Genital; 7Oropharyngeal; 194Cervical; 8Vulvo-vaginal; 7Anal; 1Oropharyngeal; 712.68 (0.25−7.69)3.7 (1.47−6.96)10.16 (8.78--11.64)1.73 (0.74--3.13)3.74 (1.48−7.02)1.88 (0.00−7.38)29.43 (22.98−36.68) Jain et al.^[@CR71]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseMen and women with diagnoses of primary invasive squamous cell carcinoma of the head and neck1979−2008Average follow-up not reported16,877Oropharyngeal; number of cases not reported136.7 (107.1−171.8) Levi et al.^[@CR72]^Retrospective cohort studySwitzerland;Vaud and Neuchatel Cancer RegistriesMen and women with diagnoses of primary oropharynx cancers1974−2003;3.9 years (average)3092Oropharyngeal; 23331.7 (27.7−36.0) Morris et al.^[@CR73]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseMen and women with primary diagnoses of oropharynx cancers1975−200669.1 months (median)8440Cervix; 7Oropharynx; 382.80 (1.28−5.32)40.16 (28.42−55.12)Total cohort has all H&N primary cancers (*N* = 75,087), Number of specificallyoropharynx primaries are a subset of the total and not reported separately in this article but assumed the same number as reported in ref. ^[@CR48]^ Neumann et al.^[@CR58]^Retrospective cohort studyFrance; K2 databaseMen and women with potentially HPV-related primary cancer diagnoses1989−2004;3.1 years (median)6049 women4078 menOropharyngeal; 3Anal; 1Oropharyngeal; 4556.26 (11.31−164.38)4.49 (0.06−24.97)26.65 (19.44--35.66)Incidence of second primary tongue and tonsil reported separately and pooled for this analysis Sikora et al.^[@CR67]^Retrospective cohort studyUSA; National Cancer Institute SEER databaseMen with primary cancer diagnoses in the tongue or tonsil;1973−20044.0 years median1973−20044.3 years median591210,752*Tonsil primary*:Anal; 2*Tongue primary*:Anal; 3Penile; 13.1 (0.4--11.1)2.3 (0.5−6.7)0.9 (0.0--4.7)Reported separately for primary tonsil and tongue cancers Soderholm et al.^[@CR74]^Retrospective cohort studyFinland; Finnish Cancer RegistryPatients with primary diagnoses of cancer in the lip or oropharynx1953−1989Average follow-up not reported (minimum = 6 months)3459Oropharyngeal; 115.8 (2.8−10.0)

Anal cancer after a primary HPV-associated cancer or preinvasive tumour {#Sec12}
-----------------------------------------------------------------------

Two studies (two comparisons)^[@CR51],[@CR66]^ reported incidence of second primary anal cancer following the same index cancer. Figure [2](#Fig2){ref-type="fig"} shows that the combined SIR for these two studies was 30.81 (95% CI 23.5−40.39) and no evidence of heterogeneity or inconsistency between the studies (*p* = 0.697, *I*^2^ = 0).Fig. 2Standardised incidence ratios of second primary cancer after HPV-associated primary tumours at the same location

Fourteen studies (28 comparisons)^[@CR44],[@CR47],[@CR48],[@CR51],[@CR54],[@CR58],[@CR62]^ reported rates of second primary anal cancer after an initial diagnosis of an independent index HPV-associated cancer. While there is considerable heterogeneity between studies grouped by primary cervical (heterogeneity *p* \< 0.001; *I*^2^ 91.5%), CIN (heterogeneity *p* \< 0.001; *I*^2^ 96.36%) and vulvo-vaginal (heterogeneity *p* = 0.018; *I*^2^ 63.4%) cancers, and also evidence of significant variation between groups (test for interaction *p* \< 0.001), the tendency towards an increase in risk is observed for all studies, and across each of the index sites. SIRs for individual index tumours ranged from 2.70 (95% CI 1.17−6.23) following an oropharyngeal index tumour to 13.69 (95% CI 8.56−21.89) after vulvo-vaginal index tumours (Fig. [3a](#Fig3){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}).Fig. 3**a** Standardised incidence ratios of anal cancer after HPV-associated primary tumours. **b** Standardised incidence ratios of cervical cancer after HPV-associated primary tumours. **c** Standardised incidence ratios of vulvo-vaginal cancer after HPV-associated primary tumours. **d** Standardised incidence ratios of oropharyngeal cancer after HPV-associated primary tumours

Cervical cancer after a primary HPV-associated cancer or preinvasive tumour {#Sec13}
---------------------------------------------------------------------------

Two studies (two comparisons)^[@CR49],[@CR51]^ reported incidence of second primary cervical cancer following a primary cervix cancer. Figure [2](#Fig2){ref-type="fig"} shows that the combined SIR for these two studies was 1.61 (95% CI 0.39−6.65) although there is evidence of heterogeneity and inconsistency between the studies (*p* = 0.005, *I*^2^ = 87.5%). Thirteen studies (17 comparisons)^[@CR43],[@CR48],[@CR51]--[@CR53],[@CR55],[@CR57],[@CR59],[@CR63],[@CR65],[@CR73]^ reported second primary cervical cancers after an independent primary HPV-associated cancer. While there is considerable heterogeneity between studies grouped by CIN (heterogeneity *p* = 0.016; *I*^2^ 59.3%) and vulvo-vaginal (heterogeneity *p* = 0.017; *I*^2^ 75.3%) index cancers, there is no evidence of variation in risk between groups (test for interaction *p* = 0.514). SIRs ranged from 1.75 (95% CI 0.66−4.67) following primary anal cancer to 5.95 (95% CI 1.39−25.47) following vulvo-vaginal cancer (Fig. [3b](#Fig3){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}).

Vulvo-vaginal cancer after a primary HPV-associated cancer or preinvasive tumour {#Sec14}
--------------------------------------------------------------------------------

Two studies (two comparisons)^[@CR51],[@CR57]^ reported incidence of second primary vulvo-vaginal cancer following the same index HAC. Figure [2](#Fig2){ref-type="fig"} shows that the combined SIR for these two studies was 9.08 (95% CI 5.46−15.12) with no evidence of heterogeneity between the studies (*p* = 0.492, *I*^2^ = 0). Nineteen studies with 24 comparisons^[@CR43],[@CR44],[@CR47],[@CR54],[@CR57],[@CR58],[@CR60],[@CR63],[@CR65],[@CR66]^ reported second primary vulvo-vaginal cancer (Fig. [3c](#Fig3){ref-type="fig"}). There is considerable heterogeneity and inconsistency between studies grouped by cervical (heterogeneity *p* \< 0.001; *I*^2^ 90.8%) and CIN (heterogeneity *p* = 0.001; *I*^2^ 68.8%) index cancers, and evidence of variation in risk between index cancer groups (test for interaction *p* = 0.001). However, an increase in risk is observed for all except three of the individual studies and to each of the index sites. The SIRs for individual index tumours ranged from 3.74 (95% CI 1.72−8.15) for oropharyngeal index tumours to 9.13 (95% CI 5.84−14.28) for index anal cancers (Fig. [3c](#Fig3){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}).

Oropharyngeal cancer after a primary HPV-associated cancer or preinvasive tumour {#Sec15}
--------------------------------------------------------------------------------

Eight studies (ten comparisons)^[@CR51],[@CR52],[@CR58],[@CR68],[@CR69],[@CR71],[@CR74]^ reported incidence of second primary oropharyngeal cancers following a cancer at the same location. Figure [2](#Fig2){ref-type="fig"} shows that the combined SIR for these studies was 22.45 (95% CI 12.70−39.68) with substantial evidence of heterogeneity between the studies (*p* \< 0.001, *I*^2^ = 98%). Twelve studies (19 comparisons)^[@CR43],[@CR44],[@CR47],[@CR48],[@CR51],[@CR52],[@CR56],[@CR57],[@CR60],[@CR64],[@CR67]^ reported second primary oropharyngeal cancer. There is considerable heterogeneity and inconsistency between studies grouped by cervical (heterogeneity *p* = 0.042; *I*^2^ 54.2%) and CIN (heterogeneity *p* \< 0.001; *I*^2^ 86.9%) and anal (heterogeneity *p* = 0.024; *I*^2^ 64.3%) index cancers, and evidence of variation in risk between index cancer groups (test for interaction *p* \< 0.001). However, a tendency towards an increase in risk is observed for the majority of individual studies, and for each of the index sites. The SIR for individual index tumours ranged from 1.72 (95% CI 1.36−2.19) for cervical index tumours to 4.87 (95% CI 1.96−12.08) for anal index tumours (Fig. [3d](#Fig3){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). As cancers of the tonsil or tongue base are specific oropharyngeal tumours strongly related to the presence of HPV, we carried out a sensitivity analysis in which we limited the meta-analysis to the six studies that specifically reported incidence rates of second primary cancers at these sites.^[@CR43],[@CR44],[@CR56],[@CR60],[@CR64],[@CR67]^ While there is less power overall, the magnitude and direction of the risks were similar to those obtained for any second cancer of the oropharynx (Figure [S1](#MOESM1){ref-type="media"}, Supplementary material).

Penile cancer after a primary HPV-associated cancer {#Sec16}
---------------------------------------------------

Just three studies^[@CR65]--[@CR67]^ representing only nine cases reported second primary penile cancer, with SIRs ranging from 0.9 (0.0−4.7) to 2.93 (0.07−16.33). Formal meta-analysis was deemed inappropriate.

Discussion {#Sec17}
==========

We have demonstrated that for patients diagnosed with HPV-associated invasive or preinvasive tumours, the risk of a second HPV-associated cancer at most sites is approximately a fivefold increase as compared with unaffected individuals; although for subsequent cervical cancers, this increase in risk is somewhat less (around 2-fold). There appears to be a particularly strong link between anal and vulvo-vaginal cancers, where either diagnosis confers around a tenfold increased risk of a second cancer at the other site. There is also a high rate of second cancers observed at the same anatomical site (acknowledging that it is difficult to differentiate recurrences from true second primary cancers from registry data in this context). For individuals this increased risk is likely to arise as a combination of exposure to high-risk HPV subtypes (so mediated by sexual behaviour) and subsequent inter- and intra-site transmission of HPV within individuals, and potentially host susceptibility where it has been suggested that mediators of immune clearance of HPV might play a role.^[@CR9],[@CR10]^

Ours is the first systematic review and meta-analysis to have estimated the risk of developing a second primary HPV-associated cancer encompassing all anogenital and oropharyngeal sites. We have included data from 32 studies representing patients from 14 countries and spanning 77 years. Anticipating heterogeneity between the studies, we planned our analyses accordingly, using a random effects model to complete the meta-analysis, grouping studies according to the index primary cancer site. We also excluded studies that did not use a contemporaneous control from the meta-analysis as we felt that studies reporting SIRs were more reliable in terms of methodological quality. Application of the SIRs produced by this approach to current incidence rates^[@CR75]^ (Table [2](#Tab2){ref-type="table"}) gives estimates that are an order of magnitude less than those seen in studies reporting an institutional cohort of index cancers (Table [S1](#MOESM1){ref-type="media"}). However, as patients included in these institutional cohort studies are likely to have been selected, and potentially followed up more intensely after primary treatment, they are more likely to have diagnosed early lesions than would be expected through a cancer registry approach. Hence, although the registry data gives a potentially more conservative estimate of second cancer risk, it is also likely to be more reliable and representative.Table 2Pooled SIRs of second HAC after primary tumours, and basal incidence, Europe and North AmericaPrimary cancerSecondary cancer, pooled SIR (95% CI)CervixVulvo-vaginalAnalOropharyngealCervix1.61 (0.39−6.65)7.76 (5.50−10.95)3.82 (2.35−6.20)1.72 (1.36−2.19)CIN2.40 (2.15−2.68)5.09 (3.85−6.73)4.47 (2.66−7.51)2.01 (1.41−2.88)Vulvo-vaginal5.95 (1.39−25.47)9.08 (5.46−15.12)13.69 (8.56−21.89)4.65 (2.36−9.16)Anal1.75 (0.66−4.67)9.13 (5.84−14.28)30.81 (23.50−40.39)4.87 (1.96−6.81)PenileNANA---3.88 (2.21−6.81)Oropharyngeal2.21 (1.33−3.66)3.74 (1.72−8.15)2.70 (1.17−6.23)22.45 (12.70−39.68)Incidence (UK)10 per 100,0004.1 per 100,0002 per 100,0003−5 per 100,000Incidence (Europe)^[@CR75]^15.2 per 100,0000.8−4.1 per 100,0001.2 per 100,0007.9 per 100,000Incidence (North America)^[@CR75]^8.1 per 100,0002.5 per 100,0001.8 per 100,0006.1 per 100,000

Misclassification of tumours in registry-based studies may introduce over- or underestimation of second cancer incidence rates. For example, differentiating between true second cancers and local recurrences (and how this pertains to progression of preinvasive disease) in practice can be difficult, and lead to classification of local recurrences as second primary lesions. Some of the included studies reported attempts to account for this, notably by excluding second cancers at the same anatomical site that were identified within the first year after diagnosis (Table [1](#Tab1){ref-type="table"}). In our meta-analyses, we have presented the rates of subsequent disease at the same site separately to try and avoid any overestimate of risk due to inclusion of local recurrences. Another opportunity for misclassification may arise due to the close anatomical proximity of anogenital cancers. Registry data might record a local recurrence that invades an adjacent organ as a second primary cancer. However, results from institutional series (that might be expected to suffer less from these problems---supplementary material Table [S1](#MOESM1){ref-type="media"}) report higher rates of second cancers suggesting this issue has not significantly inflated the SIRs seen from the registries. Finally, difficulties in discriminating tumours arising in discrete sites within the oropharynx may have led to some misclassifications and as we cannot be completely confident of tumour classifications reported within the registry studies, there may be some over- or underestimation of risk that may have occurred in the individual studies. However, the results of our planned analysis based on risk of oropharynx cancers as reported, and our sensitivity analysis looking at risk of only tongue base or tonsil cancers are broadly in keeping with one another, thus suggesting our interpretation is robust to this.

Although we anticipated that heterogeneity might be an issue and attempted to address it in our preplanned analyses, by grouping studies according to initial and second primary cancers, statistical heterogeneity is still substantial. This is likely to be due to epidemiological differences between the studies, for example different extents of follow-up times, the range of time periods covered by the studies, changing demographics of cancers over time, different selection criteria for patients and differences in treatment regimes. Moderate to high heterogeneity has also been observed in other meta-analyses of second cancer data across a range of settings,^[@CR76]^ with similar reasoning. In addition, as discussed above, over-or underestimation of second primary cancers due to difficulties in accurate classification within registry studies may also inflate the heterogeneity observed between the study results. However, almost all studies irrespective of the type and location of tumours show increases in risk of second cancer following initial primary cancer. The direction of the effect is broadly consistent, with the vast majority of studies indicating increased level of risk. The heterogeneity observed in these meta-analyses arises largely therefore due to differences in the magnitude of risk observed between studies. Therefore, while we cannot be certain of the true size of the risk, our results are indicative of an increase in risk for all of the sites assessed.

Another potential limitation is that data from studies with cervix as the primary site (whether preinvasive or invasive) predominate, given their relative incidence. It does mean that the majority of data included in our analyses are from female patients. Conversely, due to sparsity of available data, we have not been able to draw firm conclusions about the risk of second penile cancers, beyond the observation that an increased risk is consistent with the other sites of second HPV-associated tumours.

The registry data that underpins our meta-analysis were predominately derived from countries with cervical screening programmes. Effective screening routinely identifies individuals with precancerous conditions and thus reduces the subsequent risk of invasive disease. This may at least in part explain the smaller increase in risk seen for secondary cervix cancers compared to other sites. Equally hysterectomy might form part of the treatment of the initial HPV-associated cancer and as such further contribute to the lower risk of subsequent cervical cancer seen. Importantly though, cervical cancer and other HPV-associated cancers are particularly common in low and middle-income countries where screening programmes are not well established. Indeed, there is currently no coordinated surveillance after a diagnosis of a HPV-associated noncervical cancer for any population group, raising the concern that early diagnosis of curable cancer may be missed. Conversely, screening programmes (through over diagnosis) will expose patients to a range of detrimental side effects, for example in the treatment of AIN where a number of approaches are possible,^[@CR77]^ and require prospective evaluation. This is currently being undertaken in the context of men who have sex with men (MSM) and anal cancer in the SPANC trial (study for the prevention of anal cancer).^[@CR78]^ It should be noted that none of the studies included in the meta-analyses contained data on behavioural risk factors such as sexual behaviour, MSM etc. though it is likely that this will further modulate risk.

Based on our results, the diagnosis and treatment of index cancers presents an opportunity for secondary prevention, even when primary vaccination or screening is lacking. There could be the potential for therapeutic intervention using novel approaches in these patients to clear latent HPV infection or eradicate transformed cells. There is no evidence that the current prophylactic vaccines can eliminate transformed cells, though some data show that vaccination of subjects treated for HPV-associated precancers reduces the risk of new lesions in the genital tract. A small, nonrandomised cohort study of 202 patients with high-grade AIN^[@CR79]^ showed fewer subsequent diagnoses at 2 years (HR 0.50; 95% CI, 0.26--0.98; *p* = 0.05) following quadrivalent HPV vaccination. A separate study^[@CR80]^ of 737 patients with CIN2/3, treated with LEEP, also showed reduced rates of subsequent lesions in patients who subsequently received the quadrivalent HPV vaccine compared with a nonvaccinated group. Furthermore, retrospective analysis of data from randomised controlled trials of the HPV vaccine suggest that patients who developed a cervical lesion despite vaccination, and so were likely to have been infected with HPV prior to vaccination, were still relatively protected from subsequent recurrent/secondary HPV disease.^[@CR81]^ There is also considerable interest in the development of therapeutic vaccines that stimulate an immune response against established infection. Pilot studies of such approaches suggest efficacy in CIN^[@CR82]^ and larger trials including as adjuvant therapy after curative treatment of invasive cancers are in development. Finally, the growing field of immuno-oncology offers a number of approaches (for example immune checkpoint inhibitors) that might be utilised to eradicate HPV transformed cells, whether in reducing local recurrences or the development of second cancers.

In summary, there is a consistently raised incidence of each of the HPV-associated tumours as a second cancer after any such primary. Diagnosis and treatment of these index cancers presents a unique opportunity for the prevention of subsequent primary cancers. These data should inform patients and carers alike with respect to survivorship programmes. They also support new studies aimed at reducing the risks, whether through targeted screening of affected individuals, or trials of therapeutic approaches.
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